Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Ismael A. Vergara; Nigel G. Maher; Alison J. Potter; Elizabeth C. Paver; Jordan W. Conway; Serigne Lo; Andrew J. Colebatch; Georgina V. Long; James S. Wilmott; Richard A. Scolyer

doi:10.1158/1078-0432.30029213

September 2, 2025Open Access

Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

View Full Paper

Ask AI

Bookmark

Share

Key Points

The analysis identifies borderline melanocytic tumors and evaluates their malignancy.
Samples with mean target coverage below 300X were removed, ensuring high data quality.
Evaluation employed scatter plots to visualize the distribution of unique start sites across targets.
Findings may enable earlier detection and better management of melanocytic tumors.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Validation of a genomic test identifies malignancy in borderline melanocytic tumors, suggesting a novel approach.

Abstract

Scatter plot of mean target coverage and mean number of unique start sites across targets for borderline melanocytic tumors. Samples with a coverage below 300X (square shape) were deemed outliers and removed from further analysis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vergara et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f605 https://doi.org/10.1158/1078-0432.30029213

View Full Paper

Ask AI

Bookmark

Share

Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Figure S7 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading